Listed by the USPTO as JACKSON, SHAWQUIA
Tech Center 1600 • Art Units: 1623 1626 1629 1691
This examiner grants 78% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18383687 | COVALENT IMMUNE RECRUITER COMPOUNDS FOR IMMUNE CELL RECOGNITION AND ASSOCIATED USES | Non-Final OA | McMaster University |
| 18869126 | NOVEL HEPATOSELECTIVE POLYADENYLATING POLYMERASES INHIBITORS AND THEIR METHOD OF USE | Non-Final OA | The University of North Carolina at Chapel Hill |
| 18555154 | RETINOL FORMULATION (III) | Non-Final OA | DSM IP ASSETS B.V. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy78.0% of resolved applications examined by Shawquia Jackson were allowed (1,840 resolved cases), compared with 51.3% across Art Unit 1623 over the last five years.
This examiner's interview lift is -3.4 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Shawquia Jackson took 833 days on average from filing to allowance.
Shawquia Jackson examines applications in Art Unit 1623 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
